The weight-loss drug market in India is seeing big changes. Novo Nordisk has reduced the price of its popular drugs Wegovy and Ozempic.
The company cut Wegovy prices by 48% and Ozempic prices by up to 36%. The new prices started from April 1. This step comes after cheaper generic versions entered the market.
Now, the starting dose of both drugs costs about Rs. 1,415 per week. This equals nearly Rs. 202 per day. The company said the goal is to make these medicines more affordable for people in India.
Wegovy helps people lose weight and also supports heart health. Ozempic helps control blood sugar in people with type-2 diabetes. Both medicines use semaglutide, which helps control hunger and sugar levels.
The price cut comes after the patent for semaglutide ended in India. Many Indian companies quickly launched cheaper versions. These include well-known firms like Dr Reddy’s, Sun Pharma, Natco, Zydus, and Alkem.
These generic drugs cost much less. Some are priced 70% to 90% lower than earlier prices of branded drugs. This has increased competition in the market.
More companies are expected to launch similar drugs soon. Reports suggest over 40 brands may enter this segment. Many generics also come in vial form, which allows flexible dosing and lower cost for patients.
This is not the first time Novo Nordisk has reduced prices. The company had earlier cut Wegovy prices to expand its reach. The latest move shows stronger competition in the market, including from newer drugs like Mounjaro.
Vikrant Shrotriya, head of Novo Nordisk India, said the company wants to make treatment easier to afford. India faces a growing problem of diabetes and obesity. More people now need long-term treatment.
Experts believe this market will grow fast. India’s GLP-1 drugs market may rise from Rs. 1,000 crore in 2025 to around Rs. 5,000 crore by 2030. Most demand will come from diabetes care, while weight-loss use is also rising.
Even with lower prices, these medicines remain costly for many. They require a doctor’s advice and long-term use. Insurance support for weight-loss drugs is still limited in India.
The price cuts will help more people access these treatments. At the same time, strong competition may reduce profits for big companies. The Indian weight-loss drug market is now becoming more competitive and more accessible.
Also Read: Manipal Health Files IPO, Plans Rs. 8,000 Crore Raise, 4.32 Crore Shares in OFS